The ACIP recommendations for meningococcal serogroup B (MenB) vaccine say the vaccine will provide “short term protection.” What does “short term protection” mean?

MenB vaccines were approved based on the serologic response to the vaccine. No data are available on vaccine effectiveness against clinical disease or duration of protection against clinical disease. Short term protection refers to the known duration of the antibody response. Available data indicate that protective antibody levels wane in most recipients within 1–2 years of completion of the primary series.